Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

MCRC: Molecular Testing

February 8th 2020

Importance of Tumor Sidedness in mCRC

February 8th 2020

Predictive Markers for mCRC

February 8th 2020

Molecular Testing for Metastatic CRC in 2020

February 8th 2020

Dr. Harding on the Goal of the IMbrave150 trial in HCC

February 7th 2020

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).

Dr. Weinberg on the Role of Cetuximab in Metastatic CRC

February 7th 2020

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Dr. Ilson on Chemotherapy in Advanced Gastric Cancer

February 7th 2020

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

FDA Extends Review Period for Avapritinib in Fourth-Line GIST

February 7th 2020

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application for avapritinib as a treatment for adult patients with fourth-line gastrointestinal stromal tumor.

Dr. Cusnir on the Role of Ramucirumab in Gastric Cancer

February 6th 2020

Mike Cusnir, MD, discusses the utilization of ramucirumab in gastric cancer.

Dr. Putcha on the Use of Blood-Based Screening Assays in CRC

February 5th 2020

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Dr. Khan on Overall Incidence of Gastric Cancer and CRC

February 5th 2020

Amir Khan, MD, discusses trends in the overall incidence of gastric cancer and colorectal cancer.

ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year

February 5th 2020

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Dr. Puri on Challenges With Treating Older Patients With Pancreatic Cancer

February 4th 2020

Akshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.

Dr. Kahn on Rising Incidence in Gastric and CRC in Young Adult Patients

February 4th 2020

Amir Khan, MD, discusses the rising incidence of gastric and colorectal cancers in young adult patients.

Expert Advocates Moving Up Immunotherapy in MSI-H Gastric Cancer

February 3rd 2020

Modest activity has been observed with anti–PD-1 therapies for patients with gastric, esophageal, and hepatocellular carcinoma in later lines of therapy, but for patients with microsatellite instability–high tumors and other subgroups, treatment with these agents has shown benefit over chemotherapy in the first-line setting, according to recent data.

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020

Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

Treating Unresectable HCC in the Community

February 1st 2020

Sequencing With I-O Combinations in Unresectable HCC

February 1st 2020

Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020